GlassScriptPhysician profile
Anne Kronish
NPI 1467491381
$1,009.95
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $215 · 2021: $150 · 2022: $261 · 2023: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $272.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $404.79 | 2019-2023 | Mounjaro, Jardiance |
| Novo Nordisk INC | $113.50 | 2020-2023 | Wegovy |
| Exact Sciences Corporation | $106.34 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $70.46 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.56 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $43.35 | 2019 | |
| Dynavax Technologies Corporation | $39.81 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $31.68 | 2022-2023 | Hetlioz |
| Teva Pharmaceuticals USA, INC. | $29.79 | 2022 | |
| Genentech USA, INC. | $27.48 | 2020-2021 | |
| Boston Scientific Corporation | $24.27 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.67 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.01 | 2019 | |
| Amgen INC. | $14.00 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Kronish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.